跳至主要内容
临床试验/NCT07279285
NCT07279285已完成不适用

The Effect of a Sugar-free-flavored-sweet-tasting-solution on Pain Associated With Dental Injections in Pediatric Patients

University of Jordan1 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2026年1月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
54
试验地点
1
主要终点
Self-reported pain using faces pain scale-revised (FPS-r)

研究概览

简要总结

The goal of this clinical trial is to learn whether applying a sugar-free flavored sweet solution (SFSS) before local anesthesia helps reduce injection pain in children.

The main question it aims to answer is:

Does SFSS reduce pain during dental local anesthesia compared to a placebo (plain water)? Researchers will compare the use of SFSS and a placebo to see which results in lower pain scores.

Participants will:

Receive SFSS or placebo before local anesthesia during two dental visits Have their pain measured using self-reported and observational pain scales Have their heart rate monitored during the procedure

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
6 Years 至 12 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Children who are 6-12 years of age.
  • Children classified as ASA1 according to the American Society of Anesthesiologists.
  • Children who have positive (Class III) or definitely positive (Class IV) behavior during preoperative behavioral assessments according to the Frankl Scale.
  • Children who required bilateral local anesthesia infiltration injections on primary or permanent teeth either in the maxilla or mandible for dental treatment (different types of restoration, stainless steel crowns, pulp therapy, and extractions).
  • Children with positive consent forms (signed and approved by their parents/ legal guardians) and attended the appointment.

排除标准

  • Children who had a history of unpleasant experiences in dental settings.
  • Children who had a history of unpleasant experience with local anesthesia injection.
  • The presence of medically or developmentally compromising conditions.

研究组 & 干预措施

Sugar-free-flavored sweet tasting solution Group

Active Comparator

干预措施: Sugar-free-flavored sweet tasting solution (Other)

Placebo Group

Placebo Comparator

干预措施: Placebo (sterile-water) (Other)

结局指标

主要结局

Self-reported pain using faces pain scale-revised (FPS-r)

时间窗: Immediately after local anesthetic injection

Pain intensity measured using the Faces Pain Scale - Revised (FPS-R), ranging from 0 to 10, where higher scores indicate greater pain.

Self-reported pain using faces pain scale-revised (FPS-r)

时间窗: Immediately after local anesthetic injection

Pain intensity measured using the Faces Pain Scale - Revised (FPS-R), ranging from 0 to 10, where higher scores indicate greater pain.

Observer-reported pain using Revised Face, Legs, Activity, Cry, Consolability Scale

时间窗: During administration of the local anesthetic injection

Pain behavior measured using the Face, Legs, Activity, Cry, Consolability - Revised (FLACC-R) Scale, scored from 0 to 10, where higher scores indicate greater pain-related distress.

Physiological-Heart Rate

时间窗: Baseline and During Injection

Changes in heart rate measured in beats per minute (bpm); increases in heart rate indicate higher physiological arousal associated with pain

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Lamis D. Rajab

Prof

University of Jordan

研究点 (1)

Loading locations...

相似试验

已完成
1 期
Single and Multiple Dose and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-2570 Tablets in Healthy Subjects
NCT07275775InventisBio Co., Ltd100
招募中
3 期
A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)Cold Urticaria
NCT07266402Celldex Therapeutics240
招募中
1 期
Double-blind, randomized, placebo-controlled pilot clinical trial to evaluate the safety, tolerability and efficacy of two doses of a conditioned medium from a co-culture of M2 macrophages and fat-derived mesenchymal cells (PRS CK STORM) in the modulation of the cytokine storm for the treatment of acute respiratory distress syndrome (ARDS) caused by SARS-Cov-2, influenza A, influenza B and respiratory syncytial virus (RSV)
2023-507700-32-00Peaches Biotech S.L.50
招募中
1 期
Randomized, Double Blind, Placebo Controlled "first-in-human" Study to Assess the Safety and Tolerability of Single Ascending Intravenous Doses and Multiple Intravenous Doses of RA0127 in Healthy Young Volunteers
2023-504324-26-00Remab Therapeutics S.L.40
已完成
1 期
Randomized, double-blind, placebo-controlled study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of pitolisant after repeated oral ascending doses for 14 days, including the pitolisant effect on cardiac repolarization in healthy volunteers.
2023-503945-78-00Bioprojet Pharma75
Sweet-Tasting Solution Versus Placebo to Reduce Pain... | 临床试验